2025 Newsmaker: David Ricks
As of Nov. 13, Eli Lilly and Co.’s market capitalization was $967 billion and flirting with a rare $1 trillion. Its stock price in November surpassed $1,000 per share, up more than 25% for the year.
Health Care & Life Sciences
-
Lilly, IU sign clinical trial, research agreement worth up to $40M
Officials say the pact, facilitated by the Indianapolis-based IU Launch Accelerator for Biosciences, is the largest single industry-sponsored agreement in the school’s history.
Read More -
Q&A with Cory Lewis, whose emphasis on collaboration has driven INCOG’s rapid growth
Lewis sat down with IBJ to talk about his leadership style and the role of cycling in his life.
Read More -
Q&A with Elanco’s Jeff Simmons on blockbusters, challenges and growing up on a vineyard
Elanco opened the doors of its new headquarters at the former GM stamping plant site this week.
Read More -
Q&A: Urology of Indiana’s Shawn Severns on new places, new procedures
As chief operating officer, Severns oversees 14 offices at 11 sites, including the new Carmel facility on Illinois Street, that treat roughly 900 patients a day.
Read More
Articles
US regulators approve Wegovy pill for weight loss, giving Novo Nordisk an edge over Lilly
Novo Nordisk’s Wegovy pills are expected to be available within weeks, while Indianapolis-based Eli Lilly and Co. waits for approval for its daily GLP-1 pill, orforglipron.
Lilly’s growth explosion tests state’s workforce development
Eli Lilly and Co.’s career website this month listed 254 job openings in Indianapolis and another 90 in Lebanon, accounting for more than three-quarters of the 445 open positions the pharmaceutical giant listed across the United States.
Lilly Phase 3 trial shows GLP-1 pill effective for weight-loss maintenance
According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival’s GLP-1 injectable, the Indianapolis-based drugmaker said.
State health insurance plan changes reflect Braun’s vision
For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that limits choice.
Elanco announces plans to bolster Indy-based R&D, cut 300 jobs worldwide
An Elanco spokeswoman said cuts to the company’s Indiana workforce are “very minimal.” Most of the eliminated positions are from the company’s planned closure of its German R&D facility.
Lilly to build $6B plant in Alabama in 3rd of 4 big US investments
Lilly’s planned Huntsville site is part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 billion reshoring investment unveiled early this year.
Lilly cuts prices on Zepbound vials sold on LillyDirect
The decision is the latest in a series of moves to make its GLP-1 blockbuster more widely available and affordable.
Lilly rolling out direct-to-employer obesity drug coverage
The Indianapolis-based drugmaker said the coverage would be administered by third-party administrators to provide employers “transparent, flexible cost-sharing options” for their workers.
Jim Lefevere: Can state turn health innovation momentum into sustainable scale?
Yet promising health tech companies still leave the state to raise growth capital.
Roche survey: Many millennial women skipping cervical cancer screenings
Indianapolis-based Roche Diagnostics said while the survey was conducted in Europe, its implications are global and reflect challenges in the United States.
Orthopedic surgeon takes blunt approach to reforming care
Dr. Michael Meneghini waited out a two-year noncompete clause after leaving Indiana University Health before opening the $35 million Indiana Orthopedic Institute early this year.
New Indianapolis venture studio aims to launch 8-12 startups in next few years
Indianapolis-based Alloy Partners says its OneHealth Studio, a venture studio that quietly began operating last month in partnership with Elanco Animal Health Inc., will be ready to create its first startups early next year.
Elanco’s Q3 earnings top Wall Street forecasts as company continues to deal with debt
Despite reporting a loss, the company saw quarterly growth in the double digits and raised its full-year earnings estimate.
IU-Lilly study to explore drugs’ impact on job productivity
Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on weight loss drugs, including Lilly medications.
At new center, Purdue engineers will collaborate with IU doctors
Purdue University’s new Center for Musculoskeletal Engineering in Indianapolis has a growth plan that metaphorically matches a healthy growing body.
Lilly partners with Indian company to sell blockbuster weight-loss drug under new name
Per the agreement, the Indianapolis-based drugmaker will continue to manufacture the drug, which India-based Cipla will sell under a new brand name.
Brownsburg lining up incentives for $435 million life science facility
The relocated jobs would pay an average wage of $40.71 an hour, and the new jobs would pay an average wage of $45.90, according to town documents.
County-run Witham Health touts neighborly care as competition looms from a larger health system
The Lebanon-based hospital faces increased competition from large health systems that benefit from larger economies of scale and marketing budgets.
J&J lays out plan to splinter orthopedics business into separate company
The move leaves J&J focused on its pharmaceutical and MedTech segments, which make prescription drugs, contact lenses and technology to treat cardiovascular disease and help with surgeries.